Phase II trial with S-1 in chemotherapy-naıve patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG)

Cancer: Principles and Practice of Oncology.

Annals of Internal Medicine · 1991 · 8.5K citations

Medicine, Oncology, Oncology Nursing +10

Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators

Tetsuhiko Shirasaka, Yuji Shimamato, Hideyuki Ohshimo et al. · Anti-Cancer Drugs · 1996 · 824 citations

Medicine, Medicinal Chemistry, Pharmacology +16

The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent

Edmund A. Gehan · Journal of Chronic Diseases · 1961 · 670 citations

Medicine, Oncology, Pharmacology +3

Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1M tegafur–0.4M gimestat–1M otastat potassium) in advanced gastric cancer patients

Yuh Sakata, Atsushi Ohtsu, N Horikoshi et al. · European Journal of Cancer · 1998 · 564 citations

Medicine, Oncology, Pharmacology +11

Phase II Study of S-1, a Novel Oral Derivative of 5-Fluorouracil, in Advanced Gastric Cancer

Wasaburo Koizumi, Minoru Kurihara, Shuji Nakano et al. · Oncology · 2000 · 440 citations

Medicine, Oncology, Pharmacology +15